Recursion Pharmaceuticals, Inc. (BMV:RXRX)
Mexico
· Delayed Price · Currency is MXN 106.00
+3.25 (3.16%)
At close: Jul 10, 2025
Recursion Pharmaceuticals Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
Net Income | -574.78 | -463.66 | -328.07 | -239.48 | -186.48 | -87.01 | Upgrade
|
Depreciation & Amortization | 48.45 | 36.49 | 24.4 | 11.76 | 8.41 | 3.94 | Upgrade
|
Asset Writedown & Restructuring Costs | 5.96 | 0.11 | 1.19 | 2.81 | - | 0.87 | Upgrade
|
Stock-Based Compensation | 101.62 | 81.69 | 53.5 | 27.91 | 14.84 | 4.29 | Upgrade
|
Other Operating Activities | 32.82 | 24.2 | 11.45 | 8.56 | 4.92 | 1.66 | Upgrade
|
Change in Accounts Receivable | -0.19 | -6.07 | -7.76 | -0 | -5.38 | -1.12 | Upgrade
|
Change in Accounts Payable | 8.96 | 6.44 | -0.99 | 1.77 | 1.75 | -0.19 | Upgrade
|
Change in Unearned Revenue | -24.15 | -28.04 | -41.08 | 110.32 | -10 | 26.67 | Upgrade
|
Change in Other Net Operating Assets | 7.98 | -10.33 | -0.44 | -7.16 | 13.33 | 5.47 | Upgrade
|
Operating Cash Flow | -388.83 | -359.17 | -287.78 | -83.52 | -158.61 | -45.4 | Upgrade
|
Capital Expenditures | -8.87 | -13.7 | -11.96 | -37.06 | -39.8 | -5.83 | Upgrade
|
Cash Acquisitions | 277.1 | 277.1 | 1.84 | - | - | -2.6 | Upgrade
|
Sale (Purchase) of Intangibles | -3.35 | -3.35 | -0.6 | -0.3 | - | -0.9 | Upgrade
|
Investment in Securities | -1 | - | 0.48 | 230.61 | -231.95 | - | Upgrade
|
Other Investing Activities | - | - | - | - | - | 0.6 | Upgrade
|
Investing Cash Flow | 259.44 | 260.06 | -10.23 | 193.25 | -271.74 | -8.74 | Upgrade
|
Long-Term Debt Issued | - | - | - | - | - | 6.4 | Upgrade
|
Long-Term Debt Repaid | - | -4.44 | -0.77 | -0.09 | -12.8 | -0.08 | Upgrade
|
Net Debt Issued (Repaid) | -6.46 | -4.44 | -0.77 | -0.09 | -12.8 | 6.32 | Upgrade
|
Issuance of Common Stock | 337.21 | 308.56 | 140.9 | 154.44 | 471.34 | 0.68 | Upgrade
|
Financing Cash Flow | 330.75 | 304.12 | 140.13 | 154.35 | 458.54 | 246.14 | Upgrade
|
Foreign Exchange Rate Adjustments | 1.65 | -3.41 | 0.19 | -0.31 | - | - | Upgrade
|
Net Cash Flow | 203.01 | 201.6 | -157.69 | 263.76 | 28.18 | 192 | Upgrade
|
Free Cash Flow | -397.71 | -372.87 | -299.74 | -120.58 | -198.41 | -51.23 | Upgrade
|
Free Cash Flow Margin | -665.17% | -633.71% | -672.43% | -302.64% | -1949.42% | -1293.03% | Upgrade
|
Free Cash Flow Per Share | -1.26 | -1.36 | -1.44 | -0.69 | -1.58 | -2.35 | Upgrade
|
Cash Interest Paid | - | - | - | - | 0.68 | 0.99 | Upgrade
|
Levered Free Cash Flow | -204.88 | -194.33 | -187.37 | -105.41 | -121.93 | -34.61 | Upgrade
|
Unlevered Free Cash Flow | -203.59 | -193.35 | -187.31 | -105.37 | -120.09 | -33.76 | Upgrade
|
Change in Net Working Capital | -17.34 | -4.89 | 33.87 | -45.9 | -10.7 | -17.62 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.